Perspective

Mycobacterium avium: An Emerging Threat to Human Health

Hermon Taylor*

Department of Nutritional Sciences, King's College London, London, UK

DESCRIPTION

Mycobacterium avium, often referred to as MAC, is a group of bacteria that belong to the Mycobacterium family. This group encompasses several subspecies, with the most clinically significant being Mycobacterium avium subsp. Avium (MAA) and Mycobacterium avium subsp. Hominissuis (MAH). These microorganisms are commonly found in the environment, particularly in soil and water sources, and can pose a significant threat to human health. In this article, we will explore the characteristics, transmission, clinical manifestations, and treatment options for Mycobacterium avium, shedding light on this emerging health concern.

Characteristics of Mycobacterium avium

Mycobacterium avium is a Non-Tuberculous Mycobacterium (NTM), which means it is related to the bacteria responsible for tuberculosis but is distinct in many ways. MAC is characterized by its slow growth and acid-fast staining properties, which makes it difficult to diagnose and treat. These bacteria are ubiquitous in the environment, with soil and water acting as natural reservoirs. In certain circumstances, MAC can also be found in dust particles and biofilms, making exposure a common occurrence.

Transmission

Transmission of Mycobacterium avium primarily occurs through inhalation or ingestion. Individuals can become exposed to MAC through various means, such as drinking contaminated water, inhaling aerosolized particles, or contact with contaminated soil or dust. It is essential to note that MAC is not a contagious disease in the way tuberculosis is. Instead, it relies on environmental exposure and individual susceptibility.

Clinical manifestations

Mycobacterium avium infections predominantly affect individuals with compromised immune systems, such as those with HIV/AIDS, individuals undergoing chemotherapy, and transplant recipients. However, healthy individuals can also contract MAC infections, albeit less frequently.

Pulmonary infections: MAC infections often manifest in the respiratory system. Symptoms may include chronic cough, fever, chest pain, weight loss, and difficulty breathing. In some cases, MAC can mimic tuberculosis, causing diagnostic challenges.

Disseminated infections: In immunocompromised individuals, MAC can disseminate throughout the body, leading to a range of symptoms. These can include fatigue, night sweats, fever, and a significant loss of body weight. Gastrointestinal involvement may lead to abdominal pain and diarrhea.

Skin and soft tissue infections: MAC can also cause skin and soft tissue infections, leading to painful, ulcerated lesions, typically seen in immunocompromised patients.

Diagnosis

Diagnosing Mycobacterium avium infections can be challenging due to the slow growth of the bacteria and their similarity to other mycobacterial species. The diagnostic process often involves a combination of methods, including:

Sputum culture: For pulmonary infections, obtaining a sputum sample for culture is the primary diagnostic method.

Blood cultures: In cases of disseminated MAC infections, blood cultures can help identify the presence of the bacteria in the bloodstream.

Imaging studies: X-rays and CT scans can reveal the extent of lung involvement or the presence of lesions in the affected organs.

Molecular testing: Polymerase Chain Reaction (PCR) tests can identify the genetic material of the bacteria in clinical samples, allowing for more rapid and accurate diagnosis.

Treatment

The treatment of *Mycobacterium avium* infections typically involves a combination of antibiotics, as monotherapy is generally less effective due to the potential for drug resistance. Commonly used antibiotics for MAC infections include clarithromycin, azithromycin, ethambutol, and rifabutin. The specific drug regimen and duration of treatment will depend on

Correspondence to: Hermon Taylor, Department of Nutritional Sciences, King's College London, London, UK, E-mail: T.hermon@kcl.ac.uk

Received: 05-Sep-2023, Manuscript No. MDTL-23-27600; Editor assigned: 07-Sep-2023, Pre QC No. MDTL-23-27600 (PQ); Reviewed: 21-Sep-2023, QC No. MDTL-23-27600; Revised: 28-Sep-2023, Manuscript No. MDTL-23-27600 (R); Published: 05-Oct-2023, DOI: 10.35248/2161-1068.23.13.391.

Citation: Taylor H (2023) Mycobacterium avium: An Emerging Threat to Human Health. Mycobact Dis. 13:391.

Copyright: © 2023 Taylor H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

the type of infection (pulmonary, disseminated, or localized) and the patient's immune status.

It is crucial to tailor treatment to the individual patient's needs, taking into account factors such as drug interactions, potential side effects, and the presence of other underlying medical conditions. Patients with disseminated MAC infections may require long-term antibiotic therapy and close monitoring.

Prevention

Preventing Mycobacterium avium infections primarily involves reducing exposure to the bacteria. Here are some practical steps to minimize the risk:

Avoid drinking untreated water: Ensure that drinking water comes from a safe and treated source, particularly for those with weakened immune systems.

Maintain good hygiene: Proper handwashing and hygiene practices can help reduce the risk of ingestion or transmission of MAC through contact with contaminated surfaces.

Protect the lungs: In dusty or aerosolized environments, wearing a mask or respirator can reduce the risk of inhalation.

Immunization: In individuals with specific medical conditions, maintaining a robust immune system is essential. Consult with healthcare professionals regarding vaccination and preventive measures.

CONCLUSION

Mycobacterium avium is an emerging threat to human health, primarily affecting individuals with compromised immune systems. This group of bacteria, found in the environment, can cause a range of infections, including pulmonary, disseminated, and localized forms. Early diagnosis and appropriate treatment are crucial for managing MAC infections. Given the complexity of Mycobacterium avium infections and the potential for drug resistance, it is essential for healthcare professionals to remain vigilant and consider the possibility of MAC in patients with compatible symptoms. Preventative measures, including avoiding untreated water sources and maintaining good hygiene, can help reduce the risk of exposure to MAC. As our understanding of these bacteria grows, it is crucial to adapt diagnostic and treatment strategies to enhance our response to address this emerging health issue.